Sleep Disorders Pharmaceutical and Healthcare Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Sleep Disorders Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the pipeline landscape for sleep disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia, and features dormant and discontinued projects.

Restless Legs Syndrome is a neurologic disorder with a core feature of a distressing, irresistible need or urge to move the legs. Risk factors for RLS include low iron levels, kidney failure, Parkinson's disease, diabetes mellitus, rheumatoid arthritis, and pregnancy.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385279-sleep-disorders-drug-development-pipeline-review-2017

Nocturia, or nocturnal polyuria, describes the excessive urination during night time. Nocturia becomes more common with age and may be symptomatic of the use of diuretic substances, prescription drugs, edema from heart failure, insomnia, pain and prostate or bladder disorders.

Finally, insomnia is a sleep disorder that is characterized by difficulty in falling or staying asleep. Symptoms include difficulty falling asleep at night, waking up during the night, irritability, depression and anxiety.

The size of these pipelines ranges from eight products in restless legs syndrome and nocturia to 31 in insomnia. Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.

Scope
- Which companies are the most active within the pipeline for sleep disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Sleep Disorders Report Coverage 7
2.2 Restless Legs Syndrome - Overview 7
2.3 Nocturia - Overview 7
2.4 Insomnia - Overview 7
3 Therapeutics Development 8
3.1 Restless Legs Syndrome 8
3.2 Nocturia 11
3.3 Insomnia 14
4 Therapeutics Assessment 21
4.1 Restless Legs Syndrome 21
4.2 Nocturia 27
4.3 Insomnia 33
5 Companies Involved in Therapeutics Development 39
5.1 Restless Legs Syndrome 39
5.2 Nocturia 42
5.3 Insomnia 44
6 Dormant Projects 53
6.1 Restless Legs Syndrome 53
6.2 Nocturia 53
6.3 Insomnia 54
7 Discontinued Products 56
7.1 Restless Legs Syndrome 56
7.2 Insomnia 56
8 Product Development Milestones 58
8.1 Restless Legs Syndrome 58
8.2 Nocturia 63
…Continued

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/sleep-disorders-pharmaceutical-and-healthcare-pipeline-review-2017/250082

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250082

More News From thebudgetreport.com

The Latest: Macron says Brexit talks still need much work

Oct 20, 2017

BRUSSELS — The Latest on the Brexit talks between European Union leaders (all times local): 2:15 p.m. French President Emmanuel Macron says that despite the positive signals coming out of the European Union summit on the Brexit negotiations there is still "lots of progress to make if we want to pass to phase 2" and start talks on a future trade relationship. And even if some in Britain say it would be possible to walk away from the EU without any deal in place on March 29, 2019, Macron insisted that May never mentioned the possibility. Macron called speculation about...

French-led EU push for heftier tax on internet giants stalls

Oct 20, 2017

BRUSSELS — France's drive to force internet giants to pay more taxes is losing steam, amid resistance from other EU countries that offer tax shelter to companies like Apple. Under pressure from Ireland, Luxembourg and Britain, EU leaders in Brussels stopped short of calling for a Europe-wide policy for digital multinationals. The EU's 28 leaders agreed to push for "an effective and fair taxation system fit for the digital era," but said it should be an international system, not just European. Irish Prime Minister Leo Varadkar said Friday he helped convince EU partners that "we shouldn't disadvantage ourselves in terms...

World shares rise as investors await Japan vote, Fed pick

Oct 20, 2017

HONG KONG — World stock markets pushed higher Friday on investor optimism over the global outlook despite uncertainties over the outcome of political events in China and Japan and speculation over Trump's choice for the next Fed chief. KEEPING SCORE: European shares rose in early trading. France's CAC 40 rose 0.3 percent to 5,381.37 and Germany's DAX added 0.4 percent to 13,046.29. Britain's FTSE 100 climbed 0.2 percent to 7,533.85. Wall Street was poised to open higher, with Dow futures up 0.4 percent to 23,198.00 and broader S&P 500 futures rising 0.2 percent to 2,566.40. CHINA CONGRESS: Markets are keeping...

Australian car-making ends with last GM plant closing

Oct 20, 2017

CANBERRA, Australia — The last mass-produced car designed and built in Australia rolled off General Motors Co.'s production line in the industrial city of Adelaide on Friday as the nation reluctantly bid farewell to its auto manufacturing industry. GM Holden Ltd., an Australian subsidiary of the of a U.S. automotive giant, built its last car almost 70 years after it created Australia's first, the FX Holden, in 1948. Since then, an array of carmakers including Ford, Toyota, Nissan, Mitsubishi, Chrysler and Leyland have built and closed manufacturing plants in Australia. After the last gleaming red Holden VF Commodore, a six-cylinder...

George R.R. Martin mixes business, politics at film forum

Oct 20, 2017

SANTA FE, N.M. — Author and film producer George R. R. Martin waded into the politics of movie-industry tax breaks on Thursday while endorsing a prominent Democratic candidate for governor of New Mexico. Martin, a longtime Santa Fe resident and author of fantasy novels behind the "Game of Thrones" television series, made a plea to raise or eliminate New Mexico's $50 million annual limit on the state's tax incentive for film production. At an hour-long forum about New Mexico's film industry, Martin sat alongside Congresswoman Michelle Lujan Grisham, a Democratic candidate for governor in 2018 who this week announced she...